Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Peloquin

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Antimicrobial Agents and Chemotherapy|January 20, 2021
Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance SuppressionG L Drusano, Stephanie Rogers, David Brown, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 4, 2021
Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosisL H Cameron, C A Peloquin, P Hiatt, et al.
Journal of Veterinary Pharmacology and Therapeutics|February 22, 2005
Population pharmacokinetics of isoniazid in the treatment of Mycobacterium tuberculosis among Asian and African elephants (Elephas maximus and Loxodonta africana)J N Maslow, S K Mikota, M Zhu, et al.
HIV Medicine|October 30, 2009
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteersA D Luber, D V Condoluci, P D Slowinski, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 1, 2021
Effect of malnutrition on the pharmacokinetics of anti-TB drugs in Ghanaian childrenN A H Seneadza, S Antwi, H Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 18, 2002
Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreakP Spradling, D Drociuk, S McLaughlin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 13, 2019
Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing RegimensR R Kempker, L Mikiashvili, Y Zhao, et al.
The American Journal of Medicine|April 27, 1987
Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infectionsD E Nix, M F Sands, C A Peloquin, et al.
The Annals of Pharmacotherapy|September 1, 1996
Low antituberculosis drug concentrations in patients with AIDSC A Peloquin, A T Nitta, W J Burman, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2020
Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?G L Drusano, Brandon Duncanson, C A Scanga, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Antimicrobial Agents and Chemotherapy|January 20, 2021
Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance SuppressionG L Drusano, Stephanie Rogers, David Brown, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 4, 2021
Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosisL H Cameron, C A Peloquin, P Hiatt, et al.
Journal of Veterinary Pharmacology and Therapeutics|February 22, 2005
Population pharmacokinetics of isoniazid in the treatment of Mycobacterium tuberculosis among Asian and African elephants (Elephas maximus and Loxodonta africana)J N Maslow, S K Mikota, M Zhu, et al.
HIV Medicine|October 30, 2009
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteersA D Luber, D V Condoluci, P D Slowinski, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 1, 2021
Effect of malnutrition on the pharmacokinetics of anti-TB drugs in Ghanaian childrenN A H Seneadza, S Antwi, H Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 18, 2002
Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreakP Spradling, D Drociuk, S McLaughlin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 13, 2019
Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing RegimensR R Kempker, L Mikiashvili, Y Zhao, et al.
The American Journal of Medicine|April 27, 1987
Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infectionsD E Nix, M F Sands, C A Peloquin, et al.
The Annals of Pharmacotherapy|September 1, 1996
Low antituberculosis drug concentrations in patients with AIDSC A Peloquin, A T Nitta, W J Burman, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2020
Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?G L Drusano, Brandon Duncanson, C A Scanga, et al.
Pageof 8